Management of Atopic Dermatitis: The Role of Tacrolimus
Source : https://www.cureus.com/articles/110814-management-of-atopic-dermatitis-the-role-of-tacrolimus
Atopic dermatitis (AD) is a long-lasting inflammatory dermatological condition characterized by itchy, eczematous, sparsely tiny blisters that hold a clear watery substance. Additionally, the diseased skin can suppurate, occasionally with weeping with thickening of the affected skin. This is considered one of the top skin disorders involving both children and adult populations globally.
Conclusion: It was evident from the available trials, systematic reviews, and other studies that tacrolimus is equi-efficacious to glucocorticoids in ameliorating AD symptoms. Except for skin irritation or burning sensation, the safety profile of tacrolimus is similar to that of corticosteroids.
• Source: Cureus
• Conclusion/Relevance: “Tacrolimus belongs to the class of calcineurin inhibitors, which is a type of immunomodulator possessing promising efficacy in treating AD. Topical tacrolimus is an effective and safe non-corticosteroid substitute treatment for AD. We reviewed the available literature to compare and institute the safety, efficacy, and effectiveness of tacrolimus when equated to corticosteroid therapy in managing AD.”
• Treatment for AD is often unsatisfactory due to adverse effects and relapse, per the authors.
• The authors stress that the short- and long-term effects of corticosteroids are worse than tacrolimus.
• Although many studies warn of the risk of cancer (e.g., lymphoma, skin cancer) with tacrolimus use, other research has found that it does not raise risk. The authors note that tacrolimus poorly penetrates the skin as compared with corticosteroids. In clinical trials, the long-standing safety of dermal tacrolimus persisted at up to 4 years.